ABSTRACT
Background and AimsThe outbreak of Coronavirus Disease 2019 (COVID-19) may affect the disease status of patients with inflammatory bowel disease (IBD). This study aimed to assess the disease status of IBD patients in Hubei province by questionnaire online and guide to the self-management of IBD patients during this epidemic. MethodsA questionnaire was designed containing the Harvey-Bradshaw Index (HBI), the Partial Mayo Score (PMS), the short inflammatory bowel disease questionnaire (SIBDQ) and distributed to Hubei IBD patients online within one month of traffic control after the outbreak of COVID-19. This questionnaire also included some questions about patients self-report disease conditions and their epidemiological history of COVID-19. ResultsA total of 102 eligible questionnaires were included in the analysis. No patient reported infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in our study. Our result showed that 69.64% of patients with ulcerative colitis (UC) and 80.44% of patients with Crohns disease (CD) were in remission. There was not a statistically significant difference in the proportion of the active disease stage between the two types of disease (p=0.103). The majority of patients (85.29%) had a good health-related quality of life (HRQoL) (SIBDQ[≥]50). The reduction in physical exercise is a risk factor for worsening in conditions (OR=17.593, 95%CI 2.035 to 152.097, p=0.009). ConclusionsThe outbreak of COVID-19 might not have a significant impact on most Hubei IBD patients within one month after the traffic control. The patients disease condition could be assessed by our questionnaires. Doctors utilized the information and advised for IBD patients about self-management during the period of COVID-19.
ABSTRACT
Objective To analyze clinical manifestations, histology, immunohistochemistry (IHC), surgical treatment and prognosis of colorectal stromal tumours. Methods The clinical and pathological data of 30 cases of colorectal stromal tumors were analyzed retrospectively. According to Fletcher proposed approach for defining risk group in GIST, these cases were grouped into VLR, LR, IR and HR.Cox multiple regression multiple factor analysis method was used to evaluate impact factors for prognosis.Results Radical resection was achieved in all 30 cases. Tumors located in the colon in 4 ( 13% ) cases, in the rectum in 20 (67%) cases, and within the anal canal in 6 (20%) cases. C-kit expression was positive in 86. 7% cases as determined by IHC. Postoperatively, 29 cases were followed-up from 4 to 130 mos. The Fletcher proposed approach for defining risk group in GIST was closely related to the survival rates ( B =4. 226,P =0. 02). The 3- and 5-year survival rate was 73% and 53% respectively. Conclusions Surgical resection and molecular target treatment is the treatment of choice for colorectal stromal tumors. The Fletcher's classification of malignancy risk group for colorectal stromal tumors is statistically related to the modus operandi and patients' survival rate.
